by Oliver Yu
Few take FDA inspections more seriously that biotech/pharma companies. Inspections are the path to facility shutdowns. Inspections lead to 483s. 483s lead to warning letters. Warning letters lead to consent decrees.
See FDA Inspections Funnel.
There appears to be relief for those in the regulated markets. Data collected by FDAzilla (a Zymergi software licensee) shows that the FDA is conducting fewer inspections. The number of inspections started declining in Q3 2012 and bottomed out in Q2ish 2013.
In fact, the FDA has conducted fewer inspections in 2013 than in any period in the 4-years prior.
It's not clear if biologics manufacturers have benefitted. Just because the FDA is conducting fewer inspections does not mean that this decrease is impacting all areas (e.g. Food, Cosmetics, Tobacco, Drugs, Biologics, Devices...etc.) evenly.
Also, this decline in inspections appears to have little to do with the recent federal government shutdown:
That last bar (circled in red) is the shutdown.